| Subject: | FDA Issues Notice on Reminyl/Amaryl Sound Alike Dispensing and Administering Errors |
| Category: | The Joint Commission (TJC)
|
| Published: | Mon, 1 Nov 2004 - 10:00 am |
| The FDA has reported that the medication Reminyl (galantamine hydrobromide) which is a reversible, competitive acetylcholinesterase inhibitor, prescribed for the treatment of Alzheimer's related dementia, has been prescribed with the medication Amaryl (glimepiride) being dispensed and administered in error. Amaryl is an oral blood glucose lowering drug in the sulfonylurea class. The FDA reports that it appears the error is due to the sound alike nature of these two drugs, and that there has... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
Customizable Documents and Tools:
External Links:
Related MCN Products:
|
|
StayAlert!® Virtual Compliance Administrator™ keeps clients informed by email of any changes to Federal regulations, including Joint Commission (TJC, formerly JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG, and many more, and also provides downloadable tools to ensure compliance. StayAlert! is a premium product sold as an annual site-license subscription. With the site license, the client can sign up an unlimited number of users for the email alerts and access to the StayAlert! online regulatory library. The StayAlert! system was designed by healthcare professionals actively working in the healthcare environment, who were faced with attempting to competently provide quality care and services while "doing more with less". StayAlert! provides the answer to efficiently performing a variety of required job components from one centralized virtual location. StayAlert! improves data sharing and communications, thus reducing cost, broadening access and providing a system of documentation and follow-up. |
|
